Introduction
Aztreonam avibactam for Stenotrophomonas maltophilia is an emerging area of interest because this organism has intrinsic resistance mechanisms that limit the activity of many conventional β-lactam antibiotics.
Stenotrophomonas maltophilia is a Gram-negative organism that can cause healthcare-associated infections, particularly in patients with significant underlying illness or prolonged healthcare exposure.
One of the challenges in treating this organism is its production of two important β-lactamases: L1 metallo-β-lactamase and L2 serine β-lactamase.
L1 can hydrolyze many β-lactam antibiotics but does not efficiently hydrolyze aztreonam. L2, however, can hydrolyze aztreonam.
This creates a mechanistic rationale for combining aztreonam with avibactam. Aztreonam can remain stable against L1, while avibactam can inhibit the L2 β-lactamase, potentially allowing aztreonam to reach its bacterial target.
The 2026 IDSA guidance discusses aztreonam-avibactam as an alternative option for invasive S. maltophilia infections, preferably in combination with another active agent, while emphasizing that clinical and PK/PD data remain limited.
What Is Stenotrophomonas maltophilia?
Stenotrophomonas maltophilia is an aerobic Gram-negative bacterium associated primarily with healthcare settings.
It can be isolated from:
- Respiratory specimens
- Blood cultures
- Urinary specimens
- Wound or other clinical samples
The organism can cause infections particularly in patients with underlying conditions or prolonged exposure to healthcare environments.
An important distinction is that isolation of S. maltophilia does not always mean active infection. Colonization can occur, particularly in respiratory specimens.
Therefore, clinical findings and microbiological results need to be interpreted together.
Why Is S. maltophilia Difficult to Treat?
One of the major challenges is its intrinsic β-lactam resistance.
S. maltophilia produces multiple resistance mechanisms, including β-lactamases that affect the activity of conventional β-lactam antibiotics.
Two enzymes are particularly relevant to the aztreonam-avibactam combination:
L1 metallo-β-lactamase
L1 is a metallo-β-lactamase.
It can hydrolyze many β-lactam antibiotics, but aztreonam has an important advantage because it is relatively stable to hydrolysis by metallo-β-lactamases.
L2 serine β-lactamase
L2 is a serine β-lactamase that can hydrolyze aztreonam.
This creates the central problem:
L1 may spare aztreonam, but L2 can compromise it.
Avibactam provides the complementary activity by inhibiting susceptible serine β-lactamases such as L2.
How Does Aztreonam Avibactam Work Against S. maltophilia?
The mechanism can be understood in three steps.
Step 1: Aztreonam targets bacterial cell-wall synthesis
Aztreonam is a monobactam β-lactam antibiotic.
Its antibacterial activity involves binding to bacterial penicillin-binding proteins, particularly PBP3, disrupting peptidoglycan synthesis and ultimately compromising bacterial cell-wall integrity.
Step 2: L1 does not efficiently hydrolyze aztreonam
Although L1 can hydrolyze many β-lactam antibiotics, aztreonam is relatively stable against L1-mediated hydrolysis.
This provides a potential route for aztreonam to retain activity against S. maltophilia.
Step 3: Avibactam inhibits L2
The second β-lactamase creates the major challenge.
L2 can hydrolyze aztreonam, but avibactam can inhibit L2 activity.
The combination therefore uses complementary mechanisms:
Aztreonam → remains stable against L1
Avibactam → inhibits L2
Result → aztreonam can reach its bacterial target more effectively
This is mechanistically similar to the broader rationale behind aztreonam-avibactam in other β-lactamase-mediated resistance settings.
L1 and L2 β-Lactamases: The Key Difference
Understanding L1 and L2 helps explain why the combination is being investigated.
| β-Lactamase | Type | Effect on aztreonam | Role of avibactam |
|---|---|---|---|
| L1 | Metallo-β-lactamase | Does not efficiently hydrolyze aztreonam | Does not directly inhibit L1 |
| L2 | Serine β-lactamase | Can hydrolyze aztreonam | Can inhibit L2 |
| Combination | — | Aztreonam provides antibacterial activity | Avibactam protects against susceptible serine β-lactamase activity |
Important: Avibactam should not be described as an L1 or MBL inhibitor.
Its role is to inhibit susceptible serine β-lactamases.
Aztreonam Avibactam Susceptibility in S. maltophilia
Susceptibility testing is particularly important because standardized breakpoints for aztreonam-avibactam against S. maltophilia have not been established by CLSI or FDA as of the 2026 IDSA guidance.
Despite this limitation, surveillance data cited by IDSA indicate that more than 90% of S. maltophilia isolates had MICs ≤4/4 µg/mL, using the Enterobacterales breakpoint as a reference point rather than as an established S. maltophilia breakpoint.
That distinction is important.
The Enterobacterales breakpoint should not simply be presented as an officially established S. maltophilia susceptibility breakpoint.
Instead, MIC data can provide useful surveillance information while the clinical interpretation remains dependent on the available evidence.
Does Aztreonam Avibactam Have a Clinical Role in S. maltophilia?
The 2026 IDSA guidance considers aztreonam-avibactam, preferably with a second active agent, an alternative treatment option for invasive S. maltophilia infections.
However, clinical evidence remains limited.
The available clinical experience includes only a very small number of reported patients, with outcomes ranging from favorable to unfavorable.
Because the number of patients is small, these observations cannot establish a reliable clinical cure rate.
The limited evidence also means that aztreonam-avibactam should not be presented as a universally established treatment for every S. maltophilia infection.
Why Combination Therapy May Be Considered
The limited clinical and PK/PD evidence is one reason IDSA favors use of aztreonam-avibactam preferably in combination with another active agent for invasive S. maltophilia infections.
The concept is particularly relevant when:
- The infection is invasive
- The isolate demonstrates susceptibility
- Other treatment options are limited
- Clinical improvement is being monitored closely
If the patient demonstrates sustained clinical improvement and microbiological susceptibility has been established, treatment strategy may be reassessed according to the clinical situation.
This is different from claiming that combination therapy is always required or that aztreonam-avibactam is automatically appropriate for every isolate.
Aztreonam Avibactam vs Ceftazidime-Avibactam Plus Aztreonam
Another approach involving the same β-lactamase inhibitor concept is ceftazidime-avibactam plus aztreonam.
Both strategies use avibactam to inhibit susceptible serine β-lactamases while aztreonam provides the monobactam component.
However, they are not identical formulations.
Aztreonam-avibactam
The two active components are provided together as a fixed combination.
One practical advantage is synchronized exposure to aztreonam and avibactam.
Ceftazidime-avibactam plus aztreonam
This approach requires administration of two separate antibacterial components.
The 2026 IDSA guidance notes that pharmacodynamic modeling suggests similar activity between the two approaches in S. maltophilia, while single-agent administration of aztreonam-avibactam is more convenient.
Clinical data remain limited for both strategies in this organism.
Aztreonam Avibactam and Resistance
The presence of L1 and L2 enzymes is only one part of the resistance landscape.
Reduced susceptibility can potentially involve additional mechanisms, including:
- Changes in permeability
- Alterations in antibiotic targets
- Increased efflux
- β-lactamase expression or variation
- Other organism-specific resistance mechanisms
Therefore, the mechanistic rationale for aztreonam-avibactam does not eliminate the need for microbiological testing.
The broader principle is straightforward:
A resistance mechanism that is compatible with aztreonam-avibactam activity does not guarantee that every individual isolate will be susceptible.
Role of Laboratory Testing
Laboratory testing can help determine whether an individual isolate demonstrates susceptibility to available treatment options.
For S. maltophilia, interpretation of aztreonam-avibactam susceptibility requires particular caution because standardized CLSI/FDA breakpoints were not established as of the 2026 IDSA guidance.
This is an important difference from Enterobacterales, where a CLSI breakpoint is available.
For detailed background, see:
[Aztreonam Avibactam Susceptibility Testing: MIC, Breakpoints and Methods]
https://aioniospharma.com/aztreonam-avibactam-susceptibility-testing/
Aztreonam Avibactam in the Broader MBL Context
The mechanism of aztreonam-avibactam against S. maltophilia has an interesting connection with its activity against other metallo-β-lactamase-producing organisms.
The common principle is that:
- Aztreonam is relatively stable against MBL hydrolysis.
- Avibactam does not directly inhibit MBLs.
- Avibactam can inhibit susceptible serine β-lactamases that may coexist with MBLs.
However, this mechanism should not be generalized to every MBL-producing organism.
For example, the 2026 IDSA guidance notes that aztreonam-avibactam has limited activity against MBL-producing Pseudomonas aeruginosa and does not suggest it for that setting.
This demonstrates why the organism and its complete resistance profile matter.
Where Meblanios Fits in the Aztreonam Avibactam Landscape
Meblanios is an aztreonam-avibactam injection from AIONIOS Pharma.
Scientific evidence surrounding the aztreonam-avibactam combination should be distinguished from product-specific prescribing information.
For product-specific details, refer to the official product page:
[Meblanios – Aztreonam Avibactam Injection]
https://aioniospharma.com/product/meblanios/
Key Takeaways
- Stenotrophomonas maltophilia has intrinsic resistance mechanisms that make treatment challenging.
- L1 is a metallo-β-lactamase that does not efficiently hydrolyze aztreonam.
- L2 is a serine β-lactamase that can hydrolyze aztreonam.
- Avibactam can inhibit susceptible L2 activity.
- Avibactam does not directly inhibit the L1 metallo-β-lactamase.
- The 2026 IDSA guidance considers aztreonam-avibactam an alternative option for invasive S. maltophilia infections, preferably with another active agent.
- Standardized CLSI/FDA susceptibility breakpoints for aztreonam-avibactam against S. maltophilia were not established as of 2026.
- Clinical evidence remains limited and should not be interpreted as establishing a universal treatment effect.
- Susceptibility testing and clinical context remain important when evaluating treatment options.
Frequently Asked Questions
Can aztreonam-avibactam work against Stenotrophomonas maltophilia?
Aztreonam-avibactam has a mechanistic rationale and in-vitro activity against S. maltophilia. The 2026 IDSA guidance considers it an alternative option for invasive infections, preferably as part of combination therapy.
Does avibactam inhibit the L1 enzyme?
No. L1 is a metallo-β-lactamase, and avibactam does not directly inhibit metallo-β-lactamases.
Why is aztreonam useful against S. maltophilia?
Aztreonam is relatively stable against hydrolysis by the L1 metallo-β-lactamase produced by S. maltophilia.
What does avibactam do in the combination?
Avibactam inhibits susceptible serine β-lactamases, including L2, which can otherwise hydrolyze aztreonam.
Are there established aztreonam-avibactam breakpoints for S. maltophilia?
As of the 2026 IDSA guidance, CLSI and FDA susceptibility breakpoints for aztreonam-avibactam against S. maltophilia had not been established.
Is aztreonam-avibactam approved specifically for S. maltophilia?
This article discusses the scientific and clinical evidence around the combination. Product-specific approval or indication claims should be based on the applicable official product labeling rather than extrapolated from organism-level literature.